Evidence map›Paper›PMID 28327577›Full record

ArticleScientific reports2017

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.

Llewellyn E Jalbert, Adam Elkhaled, Joanna J Phillips, Evan Neill, Aurelia Williams, Jason C Crane, Marram P Olson, Annette M Molinaro, Mitchel S Berger, John Kurhanewicz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment.International journal of molecular sciences · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Magnetic resonance spectroscopy for the study of cns malignancies.Progress in nuclear magnetic resonance spectroscopy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Llewellyn E JalbertDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Adam ElkhaledDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Joanna J PhillipsDepartment of Pathology, University of California, San Francisco, CA, USA.
Evan NeillDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Aurelia WilliamsDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Jason C CraneDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Marram P OlsonDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
John KurhanewiczDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Sabrina M RonenDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Sarah J NelsonDepartment of Radiology &Biomedical Imaging, University of California, San Francisco, CA, USA.

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Institutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Metabolic Reprogramming in Brain TumorsR01CA172845 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM · 2013 to 2022
$6.3M
Impact of molecular phenotype on glioma metabolism and growthR01CA159869 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NELSON, SARAH J. · 2011 to 2015
$1.7M
NCATS NIH HHS KL2 TR001862NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA159869NCI NIH HHS R01 CA172845NCI NIH HHS T32 CA151022
6 · The paper itself

Abstract

Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used for clinical management are highly variable. A key factor in clinical decision-making is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are more likely to have a favorable outcome and be sensitive to treatment. Because of their relatively long overall median survival, more aggressive treatments are typically reserved for patients that have undergone malignant progression (MP) to an anaplastic glioma or secondary glioblastoma (GBM). In the current study, ex vivo metabolic profiles of image-guided tissue samples obtained from patients with newly diagnosed and recurrent LGG were investigated using proton high-resolution magic angle spinning spectroscopy (

Indexed as

MetabolomeMetabolomicsMutationBiopsyBrain NeoplasmsDisease ProgressionFemaleGliomaHumansIsocitrate DehydrogenaseMaleNeoplasm GradingNeoplasm StagingIsocitrate Dehydrogenase

Identifiers

PMID28327577
PMCPMC5361089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.